



(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 14/71 (2006.01)
A61K 38/17 (2006.01) C07K 14/715 (2006.01)
A61K 39/395 (2006.01) C12N 15/62 (2006.01)
A61P 37/00 (2006.01) A61K 39/00 (2006.01)
C07K 14/705 (2006.01)

(21) International Application Number:

PCT/EP2024/071329

(22) International Filing Date:

26 July 2024 (26.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/529,231 27 July 2023 (27.07.2023) US
63/599,308 15 November 2023 (15.11.2023) US

(71) Applicant: OMNILINX THERAPEUTICS AG
[CH/CH]; Grabenstrasse 3, 8952 Schlieren (CH).

(72) Inventors: FARIDMOAYER, Amirreza; Nigristweg 5,
8102 Oberengstringen (CH). FOLLADOR, Rainer; Beck-
hammer 24, 8057 Zürich (CH).

(74) Agent: JONES DAY; Prinzregentenstr. 11, 80538 Munich
(DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: ENDOCYTIC AND SCAVENGER RECEPTOR-TARGETING CHIMERIC PROTEINS AND USES THEREOF




FIG. 1

(57) Abstract: Chimeric proteins that bind to scavenger receptors (ScaR) or endocytic receptors (EnyR) and a target protein or peptide, such as a pathogenic protein or peptide and their therapeutic use in disease treatment. Upon binding of the chimeric protein to the ScaR or EnyR and the target protein, the resulting complex is internalized and subject to downstream lysosomal degradation.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*